Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1695002rdf:typepubmed:Citationlld:pubmed
pubmed-article:1695002lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:1695002lifeskim:mentionsumls-concept:C0007121lld:lifeskim
pubmed-article:1695002lifeskim:mentionsumls-concept:C0849867lld:lifeskim
pubmed-article:1695002lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:1695002lifeskim:mentionsumls-concept:C0278655lld:lifeskim
pubmed-article:1695002pubmed:dateCreated1990-8-14lld:pubmed
pubmed-article:1695002pubmed:abstractTextThe remission rates achieved with the combination of vincristine and etoposide are comparable with other frequently employed therapeutic regimens (ACO/EPICO, cisplatin/etoposide). The combination of etoposide with vincristine represents an alternative, in particular with respect to a merely palliative approach to treatment.lld:pubmed
pubmed-article:1695002pubmed:languagegerlld:pubmed
pubmed-article:1695002pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1695002pubmed:citationSubsetIMlld:pubmed
pubmed-article:1695002pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1695002pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1695002pubmed:statusMEDLINElld:pubmed
pubmed-article:1695002pubmed:monthFeblld:pubmed
pubmed-article:1695002pubmed:issn0934-8387lld:pubmed
pubmed-article:1695002pubmed:authorpubmed-author:WilkeHHlld:pubmed
pubmed-article:1695002pubmed:authorpubmed-author:ValléeDDlld:pubmed
pubmed-article:1695002pubmed:authorpubmed-author:SchmollH JHJlld:pubmed
pubmed-article:1695002pubmed:authorpubmed-author:von PawelJJlld:pubmed
pubmed-article:1695002pubmed:authorpubmed-author:DimbeckHHlld:pubmed
pubmed-article:1695002pubmed:issnTypePrintlld:pubmed
pubmed-article:1695002pubmed:volume44 Suppl 1lld:pubmed
pubmed-article:1695002pubmed:ownerNLMlld:pubmed
pubmed-article:1695002pubmed:authorsCompleteYlld:pubmed
pubmed-article:1695002pubmed:pagination582-3lld:pubmed
pubmed-article:1695002pubmed:dateRevised2009-4-7lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:meshHeadingpubmed-meshheading:1695002-...lld:pubmed
pubmed-article:1695002pubmed:year1990lld:pubmed
pubmed-article:1695002pubmed:articleTitle[Phase II study with etoposide/vincristine in small cell bronchial cancer (extensive disease)].lld:pubmed
pubmed-article:1695002pubmed:affiliationZentralkrankenhaus Gauting/München.lld:pubmed
pubmed-article:1695002pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1695002pubmed:publicationTypeEnglish Abstractlld:pubmed